Hepatitis C virus (HCV) infection remains an important global health problem with chronic infection affecting approximately 11 million children worldwide. The emergence of direct-acting antiviral (DAA) therapies and the development of non-invasive methods for the determination of liver fibrosis will significantly improve the management of paediatric patients with chronic HCV infection in subsequent years. For paediatric patients, a new era of highly effective DAA agents is beginning, and the first results of available clinical trials are very promising. In this era, the identification and monitoring of patients continues to be an important issue. The availability of non-invasive serological and imaging methods to measure hepatic fibrosis enables the identification of patients with significant or advanced liver fibrosis stages. This article summarizes the current data on the epidemiology and progress of research aimed to evaluate the new therapies and non-invasive methods for liver injury in paediatric patients with chronic hepatitis C.
INTRODUCTION
Hepatitis C virus (HCV) infection is an important public health problem recognized by the WHO. The natural history of HCV infections in children is characterized by a long asymptomatic course, with low biochemical and histopathological activity [1, 2] . The clinical symptoms of chronic HCV infection in children are not very character istic (hepatomegaly, abdominal pain, nausea, vomiting, loss of appetite, joint pain); consequently, most HCV infections are diagnosed by chance. The inability to prevent infection by vaccination, together with the serious clinical consequences of liver cirrhosis, hepatocellular carcinoma and endstage liver disease, are serious public health problems.
It is estimated that worldwide, 115185 million people (2.8%) have a chronic HCV infection [36] . In the paediatric population alone, there are more than 11 million HCV infected patients under 15 years of age, and more than 6 million of these children are viremic [7, 8] . Higher frequencies of HCV infections are recorded in countries with low and medium incomes (1.8%5%), and lower incidences are reported in countries with high incomes (0.05%0.36%) [9] . The prevalence of hepatitis C antibodies in adults in North America is estimated at 1% to 1.5% [10] , whereas it is estimated at 0.8% to 1.2% in Japan [11] , 1.1% in Ghana [12] , 1.0% in Malawi, 1.1% in Mozambique and 2.1% in Tanzania [13] . In a multicentre study, the presence of antiHCV antibodies in the central and eastern European population was reported as 0.27%3.5%. The lowest values were recorded in Kosovo, Germany, the Czech Republic and Hungary (0.3%0.6%), and the highest incidence of antiHCV antibodies was found in Lithuania, Latvia and Romania (2.4%3.5%). A study in Germany estimated the prevalence of antiHCV antibodies to be 0.3%, and positive HCV viremia was estimated at 0.2% [14] . A study in Poland estimated the prevalence of anti HCV antibodies at 0.91%, and positive HCV viremia was estimated at 0.6%, out of 278998 and 191405 patients from randomly chosen orthopaedic and trauma wards, respectively, together with health care workers and patients with diseases other than viral hepatitis [14] . In 2014, the world's highest incidence of antiHCV antibodies was recorded in Egypt at 14.7% [15] . Geographic diversity of HCV genotypes has been observed. Genotype 1 (46.2% of HCV infections) is the most widespread worldwide and is responsible for most infections in developed countries. The second most fre quent is genotype 3 (30.1% of HCV infections), which is often found in South Asia and in Europe and the US among drug users infected with HCV. Genotype 2 (9.1% of HCV infections) and genotype 6 (5.4%) are the most common genotypes found in East Asia. Genotype 4 is prevalent in North Africa and the Middle East (8.3% of HCV infections). Genotype 5 accounts for less than 1% of HCV infections and mainly appears in Africa, whereas genotype 7 infection was confirmed in Canada in 1 patient of central African origin [1618] . The prevalence of antiHCV antibodies in children varies geographically, as in the adult population. Before 1992, children treated with blood or blood products were amongst the highrisk groups for HCV infection. Before 1992, HCVinfected children acquired the virus through the transfusion of blood and bloodrelated products. Since 1992, transfused blood units have mostly been free of HCV, which is estimated to be present at a frequency of 0.001% to 0.01% per transfusion [19] . Therefore, most new HCVinfected cases have occurred through vertical transmission [8] . It is estimated that maternalfoetal transmission is responsible for more than 60% of children with HCV, and approximately 5% of infants are born to HCVRNApositive mothers [20] . The risk is higher in HCV positive women with a high viremia in their pregnancy and HIV coinfection [21, 22] . In the USA, an estimated 23000 to 46000 children live with chronic HCV. The positive presence of antiHCV antibodies has been confirmed in 0.17% of children aged 6 to 11 and in 0.39% of those aged 12 to 19, with the most common being genotype 1, followed by genotypes 2 and 3, and more rarely genotypes 4 and 6 [1, 8, 10] . In Japan, the prevalence of HCV infection in children is estimated at 0.012% in those aged 59 years, 0.010% at 1014 years, and 0.022% at 1519 years, with genotype 2 being the most prevalent in these children. Research by Mizuochi et al [23] confirmed that vertical transmission has increased and accounts for over 99% of all new HCV cases in the last decade. No transfusionrelated cases have been observed since 1994 [23, 24] . In Turkey, the prevalence of HCV infection in children and adults is estimated to be 01%, and in Syria, 1%2% [25, 26] . In India, the prevalence of HCV infection in children is estimated at 3.6% in those aged 19 years, and in Egypt, the prevalence is estimated at 2.02% in ages 19 years [27, 28] . According to Lagging et al [29] , the prevalence of chronic HCV infection is less than 0.5% among European children. During the past decade, approximately 100 such cases have been reported annually to the Swedish Public Health Agency, with half occurring in those younger than 16 years of age [30] . In light of the expected annual number of infections secondary to motherchild transmission [31] and the number of children immigrating to Sweden from countries with a higher HCV prevalence, this number may be an underestimation of the true incidence [29] . In Poland, the prevalence of HCV infection in children in the study by Gołębiowska and colleagues was estimated at 2.8% [32] . The largest group of HCVinfected children is com prised of children infected via maternalfoetal trans mission. Other groups include children with HIV infection, children with a history of multiple sexual partners, adoles cents with a history of intravenous drug use and children who are victims of sexual assault. The prevalence of substance use amongst children with HCV increased from 25% in 2006 to 41% in 2012 [33] . Screening for hepatitis C should be considered for those children with risk factors for HCV and for pregnant women.
DIRECT-ACTING ANTIVIRAL THERAPY
The development of oral interferonfree (IFNfree) anti HCV treatment with directacting antivirals (DAAs) has revolutionized the therapy of HCV infection. Currently, highly effective, safe and welltolerated antiviral regimens are available to treat adults with hepatitis C infection [34] . In 2017, the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) approved the use of the fixed-dose combination of ledipasvir/sofosbuvir and of the combination of sofosbuvir and ribavirin for the treatment of adolescents with chronic hepatitis C virus (HCV) genotypes 1, 4, 5 and 6 and genotype 2 and 3 infections, respectively. Trials with direct acting antivirals (DAAs) are ongoing for younger children. The drugs currently licensed in Europe and the US for the treatment of chronic HCV infection in children include IFN, PEG IFN, ribavirin and, recently, the fixeddose combination of ledipasvir/sofosbuvir and sofosbuvir for the treatment of adolescents aged 1217 years weighing more than 35 kg. The only drugs currently approved for children younger than 12 are PEG IFN α2a or 2b and ribavirin. Children with HCV genotypes 1 or 4 infection should be treated for 48 wk whereas those infected with genotypes 2 or 3 should be treated for 24 wk [20, 3539] . Few data are available on the paediatric use of DAAs, and 7 clinical trials are currently ongoing (NCT 3067129, NCT 2486406, NCT 3080415, NCT 2868242, NCT 2249182, NCT 3022981, NCT 2985281 [34, 40] ) ( Table 1 ). The first study assessing the IFNfree treatment of HCVinfected adolescents was a phase 2, multicentre, openlabel study that included 100 patients aged 1217 years who were infected with genotype 1 HCV who received a combination tablet of 90 mg ledipasvir and 400 mg sofosbuvir once daily for 12 wk [41] . Serial pharmacokinetic (PK) blood samples were assessed on day 10 of the study in the first 10 patients. These patients participated in a PK leadin cohort to determine the pharmacokinetics of sofosbuvir, ledipasvir and the sofosbuvir metabolite GS331007 to confirm the ap propriateness of the adult dose of ledipasvir/sofosbuvir in adolescents before additional patients were enrolled. To be eligible for the PK leadin cohort, the adolescents had to weigh > 45 kg, be naïve to HCV treatment and not have liver cirrhosis. They were administered ledipasvir/ sofosbuvir with a standardized meal with more than 400 kcal and 13 g of fat.
In the entire analysed group of adolescents, 80% were HCV treatmentnaive, 81% were infected with genotype 1a HCV, and 84% were infected through perinatal transmission. One patient had cirrhosis, and 42 did not; the degree of fibrosis was unknown in 57 patients. Of the 99 patients who completed treatment, 2 patients did not attend the followup visits at weeks 4 and 12. One of those patients completed the follow up visit at 24 wk after the end of treatment. A sustained virologic response at 12 wk (SVR 12), defined as an HCV RNA level less than the lower limit of quantification (15 IU/mL), was achieved in 98% of patients. No patient had virologic failure. The presence of resistance associated substitutions (RASs) at baseline did not affect the treatment response. All patients with a baseline presence of NS5A or NS5B RAS achieved SVR12. The most commonly reported adverse events were headache (27% of patients), diarrhoea (14%) and fatigue (13%). No serious adverse events or significant abnormalities in laboratory results were reported. Most laboratory abnormalities were mild; 1 patient had a grade 4 aspar tate aminotransferase (AST) elevation up to 573 U/L at the week 4 followup visit. This event was associated with the initiation of isotretinoin treatment for acne, and the patient's AST levels decreased and normalized. The administration of ledipasvir/sofosbuvir did not affect development as assessed by Tanner pubertal staging.
Trial identifier
Drug tested HCV genotype
NCT 3067129
Glecaprevir/pibrentasvir 1-6 NCT 2486406
Ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin 1,4 NCT 3080415 Sofosbuvir + daclatasvir 4 NCT 2868242
Ledipasvir/sofosbuvir 1,4 NCT 2249182
Ledipasvir/sofosbuvir ± ribavirin 1,4,5,6 NCT 3022981
Sofosbuvir/velpatasvir 1-6 NCT 2985281
Gratisovir + ribavirin 1-6 Table 1 Ongoing clinical trials to evaluate the safety and efficacy of direct-acting antivirals in children with chronic hepatitis C HCV: Hepatitis C virus.
safety profile of LDV/SOF but also an improvement of HRQL scores after achieving SVR, which was sustained for months after treatment cessation [46] . The preliminary results of the fixed-dose combination of ledipasvir/sofosbuvir in children aged 6 to 11 years old was presented at the International Liver Congress in 2017 [47] . This prospective, openlabel, uncontrolled trial enrolled 90 patients, all of whom received ledipasvir (45 mg) and sofosbuvir (200 mg) once daily for 12 wk. Eightysix (96%) of the patients were infected by HCV genotype 1, 18 (20%) were treatmentexperienced and 2 had cirrhosis. In total, 99% (89/90) of the treated children achieved SVR12. One genotype 1a patient with cirrhosis relapsed at the fourth followup visit. The most commonly reported adverse events were headache (19%), fever (17%) and abdominal pain (15%).
In a recently published prospective, openlabel, uncontrolled registration trial, 52 patients were treated with sofosbuvir (400 mg) once daily and weightbased ribavirin (15 mg/kg) twice daily for 12 (genotype 2) or 24 (genotype 3) wk [48] . The pharmacokinetics of sofosbuvir and its metabolite GS331007 were evalu ated by intensive plasma sampling on day 7 in the first 10 patients. Fortythree (83%) of the patients were treatmentnaïve, 73% were infected by vertical transmission and 75% had genotype 3 HCV. None of the patients who underwent liver biopsy had cirrhosis. SVR12 was achieved in 98% (51/52) of cases. The SVR12 rates were 100% (13/13) for patients with genotype 2 and 97% (38/39) for genotype 3. The single patient who did not achieve SVR12 was lost to follow up after achieving SVR4. The most commonly reported adverse events were nausea (27%) and headache (23%). Sofosbuvir and ribavirin were safe and highly effective in adolescents with chronic HCV genotype 2 or 3 infections [48] . To assess the HRQL of 50 HCVpositive adolescents treated with SOF + RBV, the patients and their parents completed the PedsQL4.0SF15 question naire at baseline, at the end of treatment and during posttreatment followup [49] . During treatment with SOF + RBV, there were no significant decrements in any of the patients' selfreported or parentreported scores, regardless of treatment duration. After treatment cessation, a statistically significant improvement in the patients' selfreported social functioning scores by post treatment week 12 was recorded. A multivariate analysis showed that a history of abdominal pain and psychiatric disorders affected impaired HRQL in adolescents with HCV (p < 0.05). Adolescents with HCV did not appear to experience any reductions in HRQL during treatment with SOF + RBV and experienced some improvements in their HRQL scores after achieving SVR.
Hashmi et al [50] assessed the effectiveness and safety of the combined administration of sofosbuvir (400 mg) once daily and ribavirin (10-15 mg/kg/d) in treatmentnaïve children with HCV infection aged 5 to 18 years. The total therapy duration was 24 wk. Thirtyfive patients with a mean age of 10.24 ± 2.80 years, including 22 boys and 13 girls, were included. The most common Ledipasvirsofosbuvir was highly effective at treating adolescents with chronic HCV genotype 1 infection. The dose of ledipasvirsofosbuvir currently used in adults was well tolerated in adolescents and had an appropriate pharmacokinetic profile [41] . No data are currently avai lable on possible shortening of the treatment to 8 wk as suggested in adults if their baseline HCV RNA level is less than 6 million (6.8 log) IU/mL [42] . Previous studies have demonstrated that both the physical and psychosocial health and cognitive func tioning of asymptomatic children with chronic HCV infection are significantly reduced compared to children without HCV [43, 44] . Chronic HCV infection has been as sociated with the impairment of healthrelated quality of life (HRQL) in both adult and paediatric patients. Nyddeger et al [43] assessed the HRQL of 19 HCVinfected
Australian children using selfreports from the children and reports from their parents. The study revealed that physical and psychosocial summary scores were significantly lower than in children not infected with HCV. This impairment was particularly notable in the General Health and Parent impactemotional scales; children with HCV also reported reduced physical functioning [43] . In a PEDSC study that included 114 HCVinfected children, caregivers assessed their children as being in poor health pretreatment, whereas the children and adolescents themselves reported scores equal to the normative population [45] . Younossi et al [46] were the first to assess HRQL in adolescents infected with genotype 1 HCV who were treated with ledipasvir/sofosbuvir. HRQL was assessed using the PedsQLv4.0SF15 completed by the children and their caregivers before, during and after treatment. The PedsQLv4.0SF15 includes 15 items that represent 4 domains of adolescent daily functioning (physical, emotional, social and school functioning). At baseline, the caregivers' and selfreported school functioning scores were significantly lower in adolescents with HCV infection (p < 0.05). All but 1 HRQL score was substantially lower when reported by caregivers compared to the adolescents' selfreports. A potential reason for the consistently lower perception of HRQL by caregivers than that reported by the adolescents themselves is that parents' perceptions may be biased by their own experience with HCV infection (84% of subjects acquired their infection prenatally). This notion is supported by the observations in the PEDSC study showing that infected mothers who had transmitted HCV to their offspring had worse HRQL compared to uninfected caregivers. At the end of treatment, no treatmentrelated impairments in HRQL scores were reported by the subjects or their caregivers. Significant improvement in the adolescents' selfreported emotional function domain was noted in the post treatment period. At the end of 24 wk of followup, all HRQL scores except for the school functioning scores became similar to the population norms without HCV [46] . This was the first clinical trial of an interferon and ribavirinfree regimen in children with HCV infection that showed not only a very high efficacy and a favourable HCV genotype was genotype 3, which was encountered in 27 (77.15%) children, followed by genotype 1 in 6 children (17.14%). Most of the patients had pre existing haematological disorders including thalassemia major, acute lymphoblastic leukaemia, nonHodgkin' s lymphoma, von Vilebrand disease and Hodgkin's disease. The most frequent mode of HCV transmission was via blood products transfusion (42.86%), followed by perinatal transmission. Thirty (85.71%) patients achieved a rapid virological response with undetectable HCV RNA by 4 wk of treatment, whereas the remaining 5 (14.28%) children were HCV RNA negative by 12 wk of treatment. An endoftreatment response was achieved for all patients, and SVR12 was achieved by 34 (97.14%) patients. The treatment was well tolerated [50] . Clinical trials of interferonfree DAA regimens have been initiated for children ages 317 years. There is hope that increased DAA uptake may prevent paediatric HCV infections by shrinking the pool of infectious persons. DAA therapies may also help reduce new vertically and horizontally acquired paediatric infections [51] . In the recently presented prospective, openlabel, uncontrolled ZIRCON trial, 38 adolescents with HCV genotype 1 or 4 infections were enrolled and treated with ombitasvir/paritaprevir/ritonavir (150/100/25 mg once daily) with dasabuvir (only for those with genotype 1 infection; 250 mg twice daily) and/or ribavirin (for all patients with genotype 1a or 4 infection; 15 mg/kg divided twice daily) [52] . All patients received 12 wk of treatment, except for one patient with an HCV genotype 1a infection with cirrhosis who was treated for 24 wk. Twentyfive (66%) of the patients were treatment naïve, and 37 (97%) were noncirrhotic. All 38 patients achieved SVR12 (100%). The most commonly reported adverse events were headache (21%) and asthenia (18%) [52] . The preliminary data from a prospective, openlabel, uncontrolled trial on combined therapy with sofosbuvir, daclatasvir with or without ribavirin (400 mg + 60 mg + 15 mg/kg) of 13 adolescents with HCV genotype 4 infection were presented. The SVR was 100% [53] . The results of the first clinical and observational trials with IFN-free therapy are very promising. The efficacy of DAAs treatment in HCV infected children was presented in Table 2 .
RECOMMENDATIONS FOR THE TREATMENT OF CHRONIC HCV

INFECTION IN CHILDREN
Although new treatments are expected to be approved for paediatric use for all age groups in the near future, there is uncertainty on the current optimal approach to treat children with chronic HCV infection [34, 54] . The Hepa tology Committee of the European Society of Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) developed an evidencebased position paper for the management of chronic HCV infection in children. This position paper addresses therapeutic management issues including goals, endpoints, indications, contra indications and the optimal treatment regimen in children with chronic HCV infection. The present position paper advocates the treatment of adolescents with chronic HCV infection and is directed to health authorities to recognize the importance of treating this special group of patients affording the cost of treatment [40] . The goal of therapy in children is to cure HCV infection to prevent the possible progression of HCVrelated liver disease and its complications (A1).
The endpoint of therapy in children is undetectable HCV RNA in the blood by a sensitive assay (lower limit of detection ≤ 15 IU/mL) 12 wk (SVR12) after the end of DAA treatment or 24 wk (SVR24) after the end of PEG IFN and ribavirin (A1).
The rationale underlying the indications for treatment of adults with chronic infection is also valid for children (B1).
All treatmentnaïve and treatmentexperienced chil dren with chronic HCV infection are considered for ther apy (A1).
Liver biopsy for obtaining liver tissue for histopath ologic examination is not routinely indicated in children with chronic HCV infection but should be evaluated case bycase (A1).
Treatment is considered without delay in the pres
Study
Patient population HCV genotype Drug Duration of therapy (wk) SVR 12 (%)
Balistreri et al [41] 100 adolescents aged 12-17 yr 1 ledipasvir 90 mg + sofosbuvir 400 mg 12 98 Murray et al [47] 90 children aged 6-11 yr 1 ledipasvir 45 mg + sofosbuvir 200 mg 12 98 Wirth et al [48] 13 adolescents aged 12-17 yr 2 sofosbuvir 400 mg + ribavirin 15 mg/kg 12 100 39 adolescents aged 12-17 yr 3 sofosbuvir 400 mg + ribavirin 15 mg/kg 24 97 Hashmi et al [50] 35 children aged 5-18 yr 3,1 sofosbuvir 400 mg + ribavirin 10-15 mg/kg 24 97 Leung et al [52] 38 adolescents 1,4 ombitasvir 150 mg + paritaprevir 100 mg + ritonavir 25 mg ± dasabuvir 250 mg ± ribavirin 12-24 100
El-Sayed et al [53] 13/18 adolescents 4 sofosbuvir 400 mg + daclatasvir 60 mg ± ribavirin 15 mg/kg 8-12 100
Table 2 Efficacy of direct-acting antivirals treatment of hepatitis C virus infected children and adolescents
HCV: Hepatitis C virus; SVR: Sustained virologic response.
ence of significant fibrosis and cirrhosis, extrahepatic manifestations and comorbidities that increase the risk of rapid evolution of liver disease (solid organ or haematopoietic stem cell transplant recipients, other patients undergoing immunosuppressive treatments) (A1). Treatment can generally be deferred in agecohorts where combined PEG IFN and ribavirin is the only treatment option (C1).
IFNfree regimens are the best options in HCV infected adolescents (> 12 years of age, weight > 35 kg), independent of the stage of liver disease and of co morbidities (C1).
PEG IFN and ribavirin have not been recommended for the treatment of HCVinfected adolescents since 2017 (C1).
Treatment of HCV genotype 1 or 4 infection: Chil dren older than 12 years who weigh > 35 kg and are chronically infected with HCV genotype 1 or 4 should be treated with the combination of ledipasvir (90 mg)/ sofosbuvir (400 mg) with a single tablet administered once daily for 12 wk (C1). The recommended duration of therapy for treatmentexperienced children with HCV genotype 1 infection and with compensated cirrhosis is 24 wk (C2).
Treatment of HCV genotype 2 or 3 infection: (1) Children older than 12 years who weigh > 35 kg and are chronically infected with HCV genotype 2 should be treated with sofosbuvir (400 mg) once daily and weight based ribavirin (15 mg/kg divided into 2 doses) for 12 wk (C1). And (2) Children older than 12 years who weigh > 35 kg and are chronically infected with HCV genotype 3 should be treated with sofosbuvir (400 mg) once daily and weight-based ribavirin (15 mg/kg divided into 2 doses) for 24 wk (C1) (Figure 1 ).
Treatment of chronic HCV infection in children younger than 12 years
PEG IFN and ribavirin are no longer recommended as a general treatment for children younger than 12 years who are infected with HCV (C1).
In children younger than 12 years, the decision to initiate therapy should be individualized to isolated cases based on the HCV genotype, severity of liver disease (as assessed by liver biopsy), potential for side effects, likelihood of response and presence of comorbidities. These cases should be referred to a centre with experi ence in the treatment of children with chronic HCV infection, and the possible offlabel use of DAAs could be considered (C1) [40] . The goal of therapy in children with chronic HCV in fection is to cure the infection. The risk of HCVrelated hepatic and extrahepatic complications in children is significantly lower than that for adults. Long-term followup paediatric studies, with combined therapy with IFN or PEGIFN + ribavirin, have shown that SVR24 corresponds to a definitive cure of HCV infection in 98% to 100% of cases [55, 56] . The availability of safe IFNfree regimens for adolescents older than 12 years and weighing > 35 kg makes these the best options in treatmentnaïve and treatmentexperienced patients, independent of the stage of liver disease and of the presence or absence of comorbidities. Consequently, the combination of PEG IFN and ribavirin is no longer recommended.
NON-INVASIVE EVALUATION OF LIVER DISEASE SEVERITY
The clinical management of children with chronic hepa titis C (CHC) remains under discussion. Prognosis, risk stratification and treatment decision depend on histo logical severity determined by liver biopsy. CHC children belong to a lowrisk group for progressive liver disease, which allows for the postponement of treatment in most children [57, 58] . Notably, at the present time, more effective and better tolerated interferonfree therapies are not yet available for children in clinical practice in the wide range they are available for adult patients. Although the degree of liver damage generally depends on age and the duration of infection, the results of available paediatric studies suggest that treatment can be postponed until adolescence or adulthood, unless patients show rarely observed progression of liver disease [35] . With the de velopment of interferonfree treatment regimens, it is reasonable to wait until adolescence or until DAAs are approved to routine clinical use for all age groups of children. Therefore, children require close follow up of their liver disease stage and grade to detect the appropriate time to begin antiviral treatment. Currently, liver biopsy remains important for the evaluation of the fibrosis grade and necro-inflammatory activity in patients with CHC, particularly in patients with concomitant HBV and HIV infection, liver steatosis or autoimmune hepatitis. However, this method has its limitations, including very small needle biopsy speci mens, which may be unrepresentative of the rest of the liver (sampling error) and difficult to omit dif ferent interpretations of the same sample by different pathologists (observer variability) [59] . In addition, liver biopsy is an invasive examination associated with possible severe complications; it is unpleasant for the patient and not suitable as a screening test or to monitor the effects of liver disease treatment. Potential complications, although rare, make the liver biopsy less accepted in paediatric patients than in adults [60] . Given these limi tations, liver biopsy among CHC children is performed much less frequently than among adults and most often applies to cases with persistent liver dysfunction or with comorbidities. Thus, almost two decades of research aimed at investigating and implementing noninvasive methods for the accurate evaluation of liver fibrosis has been important for the CHC paediatric population.
SERUM BIOMARKER TESTS
There is great interest connected to the possibility of identifying stages of liver fibrosis by using non-invasive markers based on blood tests [61] . The most extensively studied test was the FibroTest, a serological test that indirectly assesses the processes of fibrogenesis by measuring the serum levels of fibrosis biomarkers. The FibroTest consists of an algorithm that detects levels of the following 5 serum fibrosis markers: alpha-2-macroglobulin, haptoglobin, apolipoproteinA1, bilirubin and gammaglutamyltranspeptidase, resulting in scores adjusted according to age and gender, which should correspond to the histopathological fibrosis scales. ActiTest, another non-invasive test that identifies necroinflammatory activity, results in scores that should correspond to the histopathological activity scales. ActiTest uses an algorithm based on the FibroTest results and serum alanine aminotransferase (ALT) activity [62, 63] . The FibroTestActiTest has been tested and validated in adults chronically infected with HCV [64] . FibroTest ActiTest scores adjusted according to age suggest that results from adult studies should correspond to predicting advanced fibrosis in children. Currently, there are limited data on the usefulness of biomarkers in cohorts of CHC paediatric patients. The results of the few available studies that have compared serological markers with histopathological evaluations revealed that serological markers have limited clinical potential in children with CHC. In the Hermeziu et al [65] study, test results from the FibroTestActiTest were in line with histopathological METAVIR scores in 48% (10/21) of paediatric cases. Studies on children with chronic liver disease of different aetiologies showed that FibroTest scores and the APRI (aspartate aminotransferase-to-platelet ratio index) can differentiate between non-fibrosis and significant fibrosis and thus can be recommended only to detect patients with cirrhosis or significant fibrosis (METAVIR F3-F4) [66, 67] . Another study, including 50 Egyptian children with CHC, revealed the utility of the FibroTest to discriminate between patients with mild (F1) and advanced fibrosis scores at F2F4, and between patients with no fibrosis (F0) and with fibrosis (F1F4) [68] . Compared to biopsy, the overall accuracy of the FibroTest for detecting fibrosis (F1-F4) and advanced fibrosis (F2-4) was 94% and 88%, respectively. Researchers have shown the discrimination ability of the ActiTest between patients with mild and moderate activity with an overall accuracy of 90%. Addi tionally, studies demonstrated a highly significant linear correlation between the FibroTestActiTest results and the fibrosis stages and inflammation activity grades. Conversely, the Pokorska-Śpiewak et al [69] study revealed that the FibroTestActiTest was poorly correlated with the histopathological evaluation in paediatric patients with chronic viral hepatitis. We are constantly searching for new, more specific markers of liver fibrosis. A single study conducted in CHC children tested the significance of markers such as the C4a Complement [70] and inter alphatrypsin inhibitor heavy chain 4 (ITIH4) [71] , which was not associated with liver fibrosis scores but could predict significant fibrosis. The results of a recent study indicated that the noninvasive biomarkers APRI, FIB4 and AST modified by the body mass index z-score have a good to excellent performance for detecting significant liver fibrosis [72] . In addition, the authors found that these biomarkers, adjusted by the BMI zscore, perform excel lently for diagnosing significant steatosis in children with CHC.
According to these data, although serological markers do not correlate adequately with the histopathological evaluation in children, they can still be useful for select ing patients with advancedstage liver injury who should undergo liver biopsy. In fact, the assessment of the usefulness of these tests in adults indicates that they are reliable in distinguishing extreme stages of histopathological fibrosis; however, they are less effective in determining intermediate degrees of fi brosis [63] . Therefore, in children with the most prevalent intermediate stages of hepatic fibrosis progression, these tests will have limited clinical utility. Conversely, even if these tests are not as accurate as a liver biopsy, their ability to exclude liver cirrhosis becomes more important as a screening tool in all paediatric patients with chronic hepatitis C, which would allow many patients to avoid biopsy.
PHYSICAL TECHNIQUES
The rise in popularity of minimally invasive diagnoses has led to advances in radiographic techniques of imaging modalities for diagnosing hepatic fibrosis. During the past decade, new imaging techniques have become increasingly accepted for diagnosing the severity of liver disease. New radiologic imaging methods estimate liver fibrosis by assessing the tissue elasticity, which increases along with the increasing stages of fibrosis. These techniques include several types of an ultrasound based elastography such as transient elastography (TE), shear wave elastography (SWE), acoustic radiation force impulse imaging (ARFI), supersonic shearwave elastography (SSWE) and magnetic resonance elasto graphy (MRE), which is based on magnetic resonance imaging (MRI) [62, 73, 74] . All these techniques estimate tissue stiffness by measuring the velocity of the sound waves passing through the liver (shear wave velocity). The value of the shear wave (in m/s) is then converted into kilopascals to indicate liver stiffness. A higher kPa reflects a stiffer liver and more severe liver fibrosis.
Among these new techniques, TE is the most com monly used [75, 76] . The main technical limitation of Fibro scan is the inability to preview the precise location of the measurements; furthermore, there is no possibility to measure patients who have ascites or individuals who are morbidly obese [77] . The accuracy of TE has been shown to be excellent in several studies of adults with chronic hepatitis C [74, 7881] . Overall, the published studies on children and adolescents that have compared different noninvasive tools for liver stiffness measurement (LSM) with liver biopsies are limited. Welldesigned relatively large paediatric studies using LSM to predict fibrosis stages are scarce. The only paediatric study evaluating the utility of TE (FibroScan) in liver fibrosis using the METAVIER score in a cohort of 30 chronic hepatitis C patients is from Egypt by Awad et al [82] . They found that the highest predictive performance of TE was detected for liver cirrhosis, followed by advanced fibrosis (F3). The accuracy for the discrimination of liver cirrhosis and advanced fibrosis was 96.7% and 85.3% at cut-off values of 9.5 and 12.5 kPa, respectively.
Because of the lack of available studies on children with CHC, our knowledge of the usefulness of these techniques is currently primarily based on the results of research conducted on children with chronic liver disease (CLD), including nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), Wilson disease, autoimmune hepatitis or liver transplantation recipients, and finally patients with chronic viral hepatitis [66, 8393] . In 2 available studies amongst children with miscellaneous paediatric CLD including subgroups of patients with CHC, the TE (FibroScan) results were compared to liver biopsy. They provided evidence that FibroScan results were correlated with the fibrosis stages and can be reliable for distinguishing severe stages of liver fibrosis [66, 88] . Other studies in paediatric CLD patients demonstrate that ultrasoundbased elastography is a reproducible and accurate tool for identifying patients without any degree of fibrosis or significant fibrosis (F ≥ 2), with advanced fibrosis (F ≥ 3) and with cirrhosis (F4), with a detection rate > 90%. This method was less accurate in discriminating between early stages of fibrosis (F0-F2) . The authors observed that the stiffness values overlap considerably between early degrees of liver fibrosis. Although paediatric study results suggest that the fibrosis cutoff values are similar to those in adults, a small heterogeneous population does not allow for setting specific cutoff values for children [9496] . Moreover, the diagnostic high accuracy demonstrated by the authors may be overestimated because of the heterogeneity of the studies, the small sample size, the small number of children with significant or severe fibrosis and problems with interpretations of liver biopsies in children caused by the diversity of the disease. As in adults, the increased necroinflammatory grade can increase liver stiffness values and therefore can confound the prediction of liver fibrosis using ultrasound elastography [82, 84, 97] . The results of a prospective crosssectional study including a total of 90 children with 3 different aetiologies of chronic liver disease (CHC, AIH and Wilson disease) were recently shown [88] . In this study, higher elastography values for different stages in AIH patients compared to the other studied groups were observed, which according to the authors was connected to higher grades of inflammatory activity in AIH. However, AIH is a particularly prominent disease in this respect. Another study amongst CLD children showed that the presence of steatosis significantly increased the SWE values [85] . Therefore, this technique should still undergo evaluation for specific liver conditions. MR elastography is an alternative method for deter mining liver fibrosis. The main advantage of EMR is its very high accuracy of measuring liver stiffness, due to the opportunity to investigate a larger volume of liver tissue. MRE can discriminate patients with moderate and severe fibrosis from those with mild fibrosis with a high sensitivity and specificity [98] . High research costs indicate that it has limited applications in clinical practice. Currently, there are no test results using MRE to analyse liver fibrosis in a cohort of patients with CHC. Two available studies on children and adolescents with CLD who are undergoing MRE and liver biopsy showed excellent accuracy of MRE for detecting significant fibrosis [99, 100] . Moreover, by using MR elastography, Trout et al [99] confirmed the importance of a confounding effect of steatosis or inflammation of liver stiffness values on the example of a subgroup of patients with NFLD. Paediatric studies have revealed that the improved diagnostic accuracy of liver fibrosis can be reached using a combination of noninvasive methods [83, 97] . Therefore, more and more studies in children concern the clinical utility of combining 2 or more non-invasive fibrosis tests in children, and the first studies aimed at comparing the diagnostic performance of 2 imaging methods in a group of children to evaluate its correlation and utility in assessing liver fibrosis have been conducted [101] .
CONCLUSION
The largest group of children infected with HCV consists of children born with maternalfoetal HCV transmission. Other groups include children with HIV infection, ado lescents with a history of multiple sexual partners, adolescents with a history of intravenous drug use and child victims of sexual assault. Screening for hepatitis C should be considered for children with risk factors for HCV and for pregnant women. The availability of safe regimens without IFN for adolescents older than 12 years and weighing > 35 kg makes them the best option in previously untreated and experienced patients, regardless of the severity of liver disease and the presence or absence of comorbidities. Therefore, the combination of PEG IFN and ribavirin is no longer recommended. Chronic HCV infection is generally mild in children, but treatment should be an integral part of the public health approach necessary to succeed in the elimination of hepatitis C. The early identification of fibrosis in children may play a significant role in preventing the development of advanced liver disease. The noninvasive detection of paediatric cases with significant fibrosis progression can be very useful in treatment decisions. The results of available studies suggest that liver stiffness measurement methods and serum biomarker tests will help clinicians select paediatric patients with CHC who should undergo liver biopsy and can be used as a monitoring tool during followup.
